Abstract
The in vivo action of recombinant human interleukin-2 (IL-2) was investigated against the delayed type of footpad swelling to sheep red blood cells (SRBC) in B6D2F1 mice. A single intravenous injection of 1×105 of SRBC induced transient cell-mediated immunity for delayed type of hypersensitivity (DTH) which peaked four days after the immunization and diminished rapidly thereafter. IL-2 exerted both suppressive and augmentative effects, depending on the timing of its adminstration in relation to the immunization. Daily intraperitoneal injections of as much as 5× 104 Jurkat units of IL-2 from day 0 through day 3 caused marked suppression of DTH elicited on day 4. On the other hand, three or four consecutive injections of IL-2 from day 4 or day 3 through day 6 produced potent DTH on day 7, when DTH was faint, if there was any, without IL-2 administration. Potentiation of DTH was also observed when three injections of IL-2 were given from day 7 through day 9 and the antigen was challenged on day 10. These results suggest that IL-2 acts as an immunomodulator against cell-mediated immunity to SRBC in the mouse.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gillis, S., M. M. Ferm, W. Ou, andK. A. Smith. 1978. T cell growth factor: Parameters of production and quantitative microassay for activity.J. Immunol. 120:2027–2032.
Gillis, S. andK. A. Smith. 1979. Long-term culture of tumor-specific cytotoxic T cells.Nature 268:154–156.
Smith, K. A. 1980. T-cell growth factor.Immunol. Rev. 51:337–357.
Hefeneider, S. H., P. J. Conlon, C. S. Henney, andS. Gillis. 1983. In vivo interleukin-2 administration augments the generation of alloreactive cytotoxic T lymphocytes and resident natural killer cells.J. Immunol. 130:222–227.
Cheever, M. A., P. D. Greenberg, A. Fefer, andS. Gillis. 1982. Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin-2.J. Exp. Med. 155:968–980.
Pizza, G., G. Severini, D. Menniti, C. de Vinci, andF. Corrado. 1984. Tumor regression after intralesional injection of interleukin 2 (IL-2) in bladder cancer. Preliminary report.Int. J. Cancer 34:359–367.
Rosenberg, S. A., J. J. Mule, P. J. Spiess, C. L. Reichert, andS. L. Schwartz. 1985. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.J. Exp. Med. 161:1169–1188.
Stotter, H., E. Rude, andH. Wagner, 1980. T cell factor (interleukin-2) allows in vivo induction of T helper cells against heterologous erythrocytes in nude (nu/nu) mice.Eur. J. Immunol. 19:719–722.
Reed, S. G., J. A. Inverso, andS. B. Roters. 1984. Suppressed antibody responses to sheep erythrocytes in mice with chronicTrypanosoma cruzi infections were restored with interleukin 2.J. Immunol. 133:3333–3337.
Reimann, J., andT. Damantstein. 1981. Interleukin-2 allows in vivo induction of anti-erythrocyte autoantibody production in nude mice associated with the injection of rat erythrocytes.Clin. Exp. Immunol. 43:641–644.
Smith, K. A., andF. W. Ruscetti. 1981. T-cell growth factor and the culture of cloned functional T cells.Adv. Immunol. 34:137–175.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Harada, M., Mori, K. & Nishimoto, H. Suppressive and augmentative effects of recombinant human interleukin-2 upon delayed type of hypersensitivity in the mouse. Inflammation 10, 167–174 (1986). https://doi.org/10.1007/BF00915998
Issue Date:
DOI: https://doi.org/10.1007/BF00915998